Loading...

Brilliant Violet 510™ anti-human CD14 Antibody

Pricing & Availability
Clone
M5E2 (See other available formats)
Regulatory Status
RUO
Workshop
III 329
Other Names
LPS receptor
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
M5E2_BV510_CD14_Antibody_FC_082312
Human peripheral blood monocytes were stained with CD14 (clone M5E2) Brilliant Violet 510™.
  • M5E2_BV510_CD14_Antibody_FC_082312
    Human peripheral blood monocytes were stained with CD14 (clone M5E2) Brilliant Violet 510™.
Compare all formats See Brilliant Violet 510™ spectral data
Cat # Size Price Save
301841 25 tests ¥44,880
301842 100 tests ¥88,440
Description

CD14 is a 53-55 kD glycosylphosphatidylinositol (GPI)-linked membrane glycoprotein also known as LPS receptor. CD14 is expressed at high levels on monocytes and macrophages, and at lower levels on granulocytes. Some dendritic cell populations such as interfollicular dendritic cells, reticular dendritic cells, and Langerhans cells have also been reported to express CD14. As a high-affinity receptor for LPS, CD14 is involved in the clearance of gram-negative pathogens, and in the upregulation of adhesion molecules and expression of cytokines in monocytes and neutrophils.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
African Green, Capuchin Monkey, Cow, Chimpanzee, Common Marmoset, Cotton-topped Tamarin, Dog, Pigtailed Macaque, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Full-length human CD14 protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The M5E2 antibody inhibits monocyte activation and cytokine production induced by LPS. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections, blocking of LPS stimulation4, and immunofluorescence microscopy5. Clone M5E2 is not recommended for immunohistochemical staining of formalin-fixed paraffin-embedded sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 301861 and 301862).

Application References

(PubMed link indicates BioLegend citation)
  1. McMichael A, et al. 1987. Leucocyte Typing III. Oxford University Press. New York.
  2. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York. (IHC-F)
  3. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  4. Power CP, et al. 2004. J. Immunol. 173:5229. (Block)
  5. Williams KC, et al. 2001. J. Exp. Med. 193:905.
  6. Iwamoto S, et al. 2007. J. Immunol. 179:1449. (FC) PubMed
  7. Santer DM, et al. 2010. J. Immunol. 485:4739. PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Zizzo G, et al. 2012. J. Immunol. 189:3508. PubMed
  10. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  11. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. Wheatley A, et al. 2016. Sci Rep. 6: 26478. PubMed
  2. Townsley SM, et al. 2021. Cell Host Microbe. 29(4):564-578.e9. PubMed
  3. Woo MS, et al. 2021. iScience. 24(7):102752. PubMed
  4. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
  5. Marquardt I, et al. 2022. Front Microbiol. 12:752549. PubMed
  6. Sannier G, et al. 2021. Cell Reports. 36(9):109643. PubMed
  7. Eslamizar L, et al. 2021. NPJ Vaccines. 6:15. PubMed
  8. Andrews SF et al. 2019. Immunity. 51(2):398-410 . PubMed
  9. Lovelace SE, et al. 2022. iScience. 25:105067. PubMed
  10. Nielsen CM, et al. 2021. Cell Reports Medicine. 2(3):100207. PubMed
  11. Mukhamedova M, et al. 2021. Immunity. 54(4):769-780.e6. PubMed
  12. Martrus G, et al. 2017. PLoS One.. 10.1371/journal.pone.0182532. PubMed
  13. Groß R, et al. 2022. EBioMedicine. 75:103761. PubMed
  14. Sutton HJ, et al. 2021. Cell Reports. 34(6):108684. PubMed
  15. Jegaskanda S, et al. 2019. JCI Insight. 4:e129035. PubMed
  16. Kuri-Cervantes L, et al. 2020. STAR Protoc. 1:100154. PubMed
  17. Demers K, et al. 2016. PLoS Pathog. 12: 1005805. PubMed
  18. van der Ploeg K, et al. 2022. Cell Rep Med. 3:100640. PubMed
  19. Juno JA, et al. 2020. Nat Med. 26:1428. PubMed
  20. Wheatley AK, et al. 2021. Cell Rep. 37:109822. PubMed
  21. Minassian AM, et al. 2021. Med (N Y). 2:701. PubMed
  22. Tan J, et al. 2021. Sci Transl Med. 13: . PubMed
  23. Nguyen THO, et al. 2021. Immunity. 54:1066. PubMed
  24. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
  25. Cassetta L et al. 2019. Cancer Cell. 35(4):588-602 . PubMed
  26. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  27. Asokan M, et al. 2020. Proc Natl Acad Sci U S A. 117:18754. PubMed
  28. Rutishauser L, et al. 2017. AIDS Res Hum Retroviruses . 10.1089/AID.2016.0324. PubMed
  29. Silver J, et al. 2020. Methods Mol Biol. 2121:115. PubMed
  30. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  31. Hubbard JJ, et al. 2020. J Exp Med. :217. PubMed
  32. Bradley T et al. 2018. Cell. 175(2):387-399 . PubMed
  33. Sperk M, et al. 2021. iScience. 24:102111. PubMed
  34. Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed
  35. Zabaleta N, et al. 2021. Cell Host Microbe. :. PubMed
  36. Morris AB, et al. 2020. Immunity. 52(1):136-150.e6.. PubMed
  37. Gao Y, et al. 2022. Immunity. 55:1732. PubMed
  38. Peluso MJ, et al. 2021. Cell Rep. 36:109518. PubMed
  39. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  40. Castro I, et al. 2016. J Virol. 90: 5280 - 5291. PubMed
  41. Martins M, et al. 2015. J Virol. 89: 10802 - 10820. PubMed
  42. Gomez–Ospina N, et al. 2019. Nat Commun. 3.225694444. PubMed
  43. Moguche AO et al. 2017. Cell host & microbe. 21(6):695-706 . PubMed
  44. Escudero–Pérez B, et al. 2019. JCI Insight. 4:e126070. PubMed
  45. Rakshit S, et al. 2020. Cell Rep. 33:108451. PubMed
  46. Graham C, et al. 2021. Immunity. 54(6):1276-1289.e6. PubMed
  47. Sekine T, et al. 2020. Cell. 183:158. PubMed
  48. Townsley SM, et al. 2021. STAR Protocols. 2(3):100771. PubMed
  49. Liu Y, et al. 2019. Nat Commun. 10:324. PubMed
  50. Sagebiel AF, et al. 2019. Nat Commun. 10:975. PubMed
  51. Wang L, et al. 2021. Science. 373:. PubMed
  52. NULL, et al. 2022. Cell. 185:916. PubMed
  53. Glaser K, et al. 2016. PLoS One. 11: 0146898. PubMed
  54. Colby DJ, et al. 2018. Nat Med. 24:923. PubMed
  55. Dacon C, et al. 2022. Cell Host Microbe. Online ahead of print. PubMed
  56. Wang Z, et al. 2020. J Cell Mol Med. . PubMed
  57. Li D, et al. 2020. Immunohorizons. 0.661805556. PubMed
  58. Baxter AE, et al. 2017. Nat Protoc. 12:2029. PubMed
  59. Theurich S et al. 2017. Cell metabolism. 26(1):171-184 . PubMed
  60. Cho H, et al. 2021. Sci Transl Med. 13:eabj5413. PubMed
  61. Akusjärvi SS, et al. 2022. iScience. 25:103607. PubMed
  62. Abd Hamid M et al. 2019. Cancer Immunol Res. 7(8):1293-1306 . PubMed
  63. Garfall AL, et al. 2018. JCI Insight. 3. PubMed
  64. Giron LB, et al. 2020. EBioMedicine. 73.94791667. PubMed
  65. Woda M, et al. 2016. J Infect Dis. 214: 1001 - 1009. PubMed
  66. Luoma AM, et al. 2020. Cell. 182(3):655-671.e22. PubMed
  67. Scharenberg SG, et al. 2020. Nat Commun. 2.76875. PubMed
RRID
AB_2561379 (BioLegend Cat. No. 301841)
AB_2561946 (BioLegend Cat. No. 301842)

Antigen Details

Structure
GPI-linked membrane glycoprotein, 53-55 kD
Distribution

Monocytes, macrophages, granulocytes (low)

Function
LPS receptor, clearance of Gram-negative pathogens
Ligand/Receptor
LPS
Cell Type
Granulocytes, Macrophages, Monocytes, Neutrophils
Biology Area
Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience
Molecular Family
CD Molecules
Antigen References

1. Stocks S, et al. 1990. Biochem. J. 268:275.
2. Wright S, et al. 1990. Science 249:1434.

Gene ID
929 View all products for this Gene ID
UniProt
View information about CD14 on UniProt.org

Other Formats

View All CD14 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD14 M5E2 FC
FITC anti-human CD14 M5E2 FC
PE anti-human CD14 M5E2 FC
Purified anti-human CD14 M5E2 FC,CyTOF®,Block,IHC-F
PE/Cyanine7 anti-human CD14 M5E2 FC
Alexa Fluor® 488 anti-human CD14 M5E2 FC
Alexa Fluor® 647 anti-human CD14 M5E2 FC
Ultra-LEAF™ Purified anti-human CD14 M5E2 FC,CyTOF®,Block,IHC-F
Pacific Blue™ anti-human CD14 M5E2 FC
APC/Cyanine7 anti-human CD14 M5E2 FC
Alexa Fluor® 700 anti-human CD14 M5E2 FC
PerCP/Cyanine5.5 anti-human CD14 M5E2 FC
Biotin anti-human CD14 M5E2 FC
Brilliant Violet 421™ anti-human CD14 M5E2 FC
Brilliant Violet 570™ anti-human CD14 M5E2 FC
Brilliant Violet 605™ anti-human CD14 M5E2 FC
Brilliant Violet 650™ anti-human CD14 M5E2 FC
Brilliant Violet 711™ anti-human CD14 M5E2 FC
Brilliant Violet 785™ anti-human CD14 M5E2 FC
Brilliant Violet 510™ anti-human CD14 M5E2 FC
Purified anti-human CD14 (Maxpar® Ready) M5E2 FC,CyTOF®
PerCP anti-human CD14 M5E2 FC
FITC anti-human CD14 M5E2 FC
PE/Dazzle™ 594 anti-human CD14 M5E2 FC
Pacific Blue™ anti-human CD14 M5E2 FC
APC/Fire™ 750 anti-human CD14 M5E2 FC
APC anti-human CD14 M5E2 FC
TotalSeq™-A0081 anti-human CD14 M5E2 PG
TotalSeq™-B0081 anti-human CD14 M5E2 PG
TotalSeq™-C0081 anti-human CD14 M5E2 PG
PE anti-human CD14 M5E2 FC
PE/Cyanine5 anti-human CD14 M5E2 FC
TotalSeq™-D0081 anti-human CD14 M5E2 PG
APC/Fire™ 750 anti-human CD14 M5E2 FC
GMP FITC anti-human CD14 M5E2 FC
PE/Cyanine7 anti-human CD14 M5E2 FC
GMP APC anti-human CD14 M5E2 FC
GMP PE anti-human CD14 M5E2 FC
PE/Dazzle™ 594 anti-human CD14 M5E2 FC
GMP Pacific Blue™ anti-human CD14 M5E2 FC
GMP APC/Fire™ 750 anti-human CD14 M5E2 FC
PerCP/Cyanine5.5 anti-human CD14 M5E2 FC
Spark Violet™ 500 anti-human CD14 M5E2 FC
GMP PE/Dazzle™ 594 anti-human CD14 M5E2 FC
Go To Top Version: 4    Revision Date: 11/05/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account